Human pancreatic growth hormone-releasing factor (hpGRF): Dose-response of GRF- and GH-levels

M. Losa, G. K. Stalla, O. A. Müller, K. von Werder

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Synthetic human pancreatic growth hormone-releasing factor (hpGRF1–44) was given as an i.v. bolus to 8 healthy volunteers in 5 different dosages. Blood was collected before and up to 120 min after GRF-injection. Four subjects received only placebo, five received 3.3 µg, three 12.5 µg, four 50 µg, 5 received 100 µg, and three 200 µg hpGRF1–44. No serious side effects were recorded after hpGRF1–44. All dosages with the exception of the 3.3 µg-dosage lead to a clearcut and significant increase of GH-levels with a maximum occurring 15 to 30 minutes after hpGRF1–44. A dose-response-relationship between the injected GRF-dosage and growth hormone levels was only found from 3.3 to 50 µg hpGRF1–44. The administration of 100 or 200 µg hpGRF1–44 did not lead to a further increase of GH-levels compared to the 50-µg-dose. This was in contrast to the clearcut dose dependency of hpGRF1–44-levels measured by a specific radioimmunoassay over the whole dose range with a maximum occurring 5 minutes after the injection. The mean halftime of disappearance for the 200-µg-dose of hp-GRF1–44 was 7.6±1.7 minutes (±SE). We conclude that there is a marked heterogeneity of the GH-response to hpGRF1–44 in healthy volunteers though a dose-response-relationship over the range from 3.3 to 50 µg hpGRF i.v. could be established. The dose-response-dependency of hpGRF1–44-levels up to the 200-µg-dose indicates that the maximal GH-response is reached when 50 µg hpGRF1–44 are administered. Therefore the test for routine purposes should be performed with 50 µg or 1 µg/kg body weight i.v.

Original languageEnglish
Pages (from-to)1249-1253
Number of pages5
JournalKlinische Wochenschrift
Volume61
Issue number24
DOIs
Publication statusPublished - 1983

Fingerprint

Growth Hormone-Releasing Hormone
Healthy Volunteers
Injections
Growth Hormone
Radioimmunoassay
Placebos
Body Weight

Keywords

  • Growth hormone
  • Growth hormone-releasing factor (GRF)
  • Radioimmunoassay of GRF and GH

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Human pancreatic growth hormone-releasing factor (hpGRF) : Dose-response of GRF- and GH-levels. / Losa, M.; Stalla, G. K.; Müller, O. A.; von Werder, K.

In: Klinische Wochenschrift, Vol. 61, No. 24, 1983, p. 1249-1253.

Research output: Contribution to journalArticle

Losa, M. ; Stalla, G. K. ; Müller, O. A. ; von Werder, K. / Human pancreatic growth hormone-releasing factor (hpGRF) : Dose-response of GRF- and GH-levels. In: Klinische Wochenschrift. 1983 ; Vol. 61, No. 24. pp. 1249-1253.
@article{48f90944ef2945d9a438a131b235d3da,
title = "Human pancreatic growth hormone-releasing factor (hpGRF): Dose-response of GRF- and GH-levels",
abstract = "Synthetic human pancreatic growth hormone-releasing factor (hpGRF1–44) was given as an i.v. bolus to 8 healthy volunteers in 5 different dosages. Blood was collected before and up to 120 min after GRF-injection. Four subjects received only placebo, five received 3.3 µg, three 12.5 µg, four 50 µg, 5 received 100 µg, and three 200 µg hpGRF1–44. No serious side effects were recorded after hpGRF1–44. All dosages with the exception of the 3.3 µg-dosage lead to a clearcut and significant increase of GH-levels with a maximum occurring 15 to 30 minutes after hpGRF1–44. A dose-response-relationship between the injected GRF-dosage and growth hormone levels was only found from 3.3 to 50 µg hpGRF1–44. The administration of 100 or 200 µg hpGRF1–44 did not lead to a further increase of GH-levels compared to the 50-µg-dose. This was in contrast to the clearcut dose dependency of hpGRF1–44-levels measured by a specific radioimmunoassay over the whole dose range with a maximum occurring 5 minutes after the injection. The mean halftime of disappearance for the 200-µg-dose of hp-GRF1–44 was 7.6±1.7 minutes (±SE). We conclude that there is a marked heterogeneity of the GH-response to hpGRF1–44 in healthy volunteers though a dose-response-relationship over the range from 3.3 to 50 µg hpGRF i.v. could be established. The dose-response-dependency of hpGRF1–44-levels up to the 200-µg-dose indicates that the maximal GH-response is reached when 50 µg hpGRF1–44 are administered. Therefore the test for routine purposes should be performed with 50 µg or 1 µg/kg body weight i.v.",
keywords = "Growth hormone, Growth hormone-releasing factor (GRF), Radioimmunoassay of GRF and GH",
author = "M. Losa and Stalla, {G. K.} and M{\"u}ller, {O. A.} and {von Werder}, K.",
year = "1983",
doi = "10.1007/BF01540473",
language = "English",
volume = "61",
pages = "1249--1253",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "24",

}

TY - JOUR

T1 - Human pancreatic growth hormone-releasing factor (hpGRF)

T2 - Dose-response of GRF- and GH-levels

AU - Losa, M.

AU - Stalla, G. K.

AU - Müller, O. A.

AU - von Werder, K.

PY - 1983

Y1 - 1983

N2 - Synthetic human pancreatic growth hormone-releasing factor (hpGRF1–44) was given as an i.v. bolus to 8 healthy volunteers in 5 different dosages. Blood was collected before and up to 120 min after GRF-injection. Four subjects received only placebo, five received 3.3 µg, three 12.5 µg, four 50 µg, 5 received 100 µg, and three 200 µg hpGRF1–44. No serious side effects were recorded after hpGRF1–44. All dosages with the exception of the 3.3 µg-dosage lead to a clearcut and significant increase of GH-levels with a maximum occurring 15 to 30 minutes after hpGRF1–44. A dose-response-relationship between the injected GRF-dosage and growth hormone levels was only found from 3.3 to 50 µg hpGRF1–44. The administration of 100 or 200 µg hpGRF1–44 did not lead to a further increase of GH-levels compared to the 50-µg-dose. This was in contrast to the clearcut dose dependency of hpGRF1–44-levels measured by a specific radioimmunoassay over the whole dose range with a maximum occurring 5 minutes after the injection. The mean halftime of disappearance for the 200-µg-dose of hp-GRF1–44 was 7.6±1.7 minutes (±SE). We conclude that there is a marked heterogeneity of the GH-response to hpGRF1–44 in healthy volunteers though a dose-response-relationship over the range from 3.3 to 50 µg hpGRF i.v. could be established. The dose-response-dependency of hpGRF1–44-levels up to the 200-µg-dose indicates that the maximal GH-response is reached when 50 µg hpGRF1–44 are administered. Therefore the test for routine purposes should be performed with 50 µg or 1 µg/kg body weight i.v.

AB - Synthetic human pancreatic growth hormone-releasing factor (hpGRF1–44) was given as an i.v. bolus to 8 healthy volunteers in 5 different dosages. Blood was collected before and up to 120 min after GRF-injection. Four subjects received only placebo, five received 3.3 µg, three 12.5 µg, four 50 µg, 5 received 100 µg, and three 200 µg hpGRF1–44. No serious side effects were recorded after hpGRF1–44. All dosages with the exception of the 3.3 µg-dosage lead to a clearcut and significant increase of GH-levels with a maximum occurring 15 to 30 minutes after hpGRF1–44. A dose-response-relationship between the injected GRF-dosage and growth hormone levels was only found from 3.3 to 50 µg hpGRF1–44. The administration of 100 or 200 µg hpGRF1–44 did not lead to a further increase of GH-levels compared to the 50-µg-dose. This was in contrast to the clearcut dose dependency of hpGRF1–44-levels measured by a specific radioimmunoassay over the whole dose range with a maximum occurring 5 minutes after the injection. The mean halftime of disappearance for the 200-µg-dose of hp-GRF1–44 was 7.6±1.7 minutes (±SE). We conclude that there is a marked heterogeneity of the GH-response to hpGRF1–44 in healthy volunteers though a dose-response-relationship over the range from 3.3 to 50 µg hpGRF i.v. could be established. The dose-response-dependency of hpGRF1–44-levels up to the 200-µg-dose indicates that the maximal GH-response is reached when 50 µg hpGRF1–44 are administered. Therefore the test for routine purposes should be performed with 50 µg or 1 µg/kg body weight i.v.

KW - Growth hormone

KW - Growth hormone-releasing factor (GRF)

KW - Radioimmunoassay of GRF and GH

UR - http://www.scopus.com/inward/record.url?scp=0021080183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021080183&partnerID=8YFLogxK

U2 - 10.1007/BF01540473

DO - 10.1007/BF01540473

M3 - Article

C2 - 6420609

AN - SCOPUS:0021080183

VL - 61

SP - 1249

EP - 1253

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 24

ER -